Tengiz Makharadze

Tengiz Makharadze
Name	Tengiz Makharadze
Native name	თენგიზ მაჩარაძე
Birth date	1949
Birth place	Tbilisi, Georgian SSR, Soviet Union
Occupation	Cardiologist, pharmacologist, medical researcher, educator
Alma mater	Tbilisi State Medical Institute
Known for	Clinical pharmacology, cardiology research, antihypertensive therapies

Tengiz Makharadze was a Georgian physician and clinical pharmacologist noted for contributions to cardiovascular therapeutics and clinical trials originating from the Georgian Soviet Socialist Republic and post-Soviet Georgia. He combined clinical practice with experimental pharmacology, participating in multinational collaborations that connected research centers in Tbilisi with institutions in Moscow, London, Berlin, Paris, and Boston. His work influenced treatment guidelines adopted by regional health authorities and informed translational studies in antihypertensive and antiarrhythmic agents.

Early life and education

Born in Tbilisi during the era of the Georgian Soviet Socialist Republic, he completed secondary schooling influenced by the scientific culture of institutions such as the Tbilisi State Medical Institute and the Tbilisi State University. He undertook medical training at the Tbilisi State Medical Institute, where he studied under clinicians associated with the Academy of Sciences of the USSR and collaborated with departments linked to the Ministry of Health of the USSR and regional hospitals in Kakheti and Adjara. Postgraduate studies included residency rotations aligned with research groups from the Institute of Cardiology (Moscow) and exchanges with specialists from the All-Union Institute of Experimental Medicine and the First Pavlov State Medical University of St. Petersburg.

Medical and research career

Makharadze's early appointments combined clinical cardiology at major Tbilisi hospitals with laboratory work in pharmacology at the Tbilisi State Medical Institute and affiliated institutes within the Georgian Academy of Sciences. He led clinical pharmacology units that conducted randomized clinical trials in cooperation with pharmaceutical centers in Moscow, Berlin, Paris, and London and participated in multicenter studies coordinated by networks tied to the World Health Organization and the European Society of Cardiology. His research methodology drew on standards promulgated by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and clinical trial designs influenced by protocols used at the Massachusetts General Hospital and the Royal Brompton Hospital.

He served as principal investigator on studies assessing vasodilators, ACE inhibitors, beta-blockers, and novel antiarrhythmic compounds, applying pharmacokinetic and pharmacodynamic techniques described in literature from the Max Planck Institute and the Karolinska Institute. Collaborative publications appeared alongside researchers affiliated with the Ludwig Maximilian University of Munich, the University of Oxford, the University of Paris, and the Harvard Medical School.

Contributions to cardiology and pharmacology

Across his career, Makharadze contributed to evidence on antihypertensive regimens and cardiac electrophysiology, integrating findings from experimental pharmacology with clinical endpoints used by the European Society of Hypertension and the American Heart Association. His trials evaluated outcomes such as systolic and diastolic blood pressure reductions, arrhythmia burden, and heart failure parameters, referencing biomarkers and imaging standards promoted by the European Society of Cardiology and validated by laboratories modeled on the National Institutes of Health.

He participated in guideline development discussions that intersected with recommendations from the World Health Organization, the European Medicines Agency, and national ministries including the Ministry of Labour, Health and Social Affairs (Georgia). His translational work connected molecular pharmacology techniques from the Pasteur Institute and the Salk Institute with clinical endpoints employed by tertiary centers such as the Charité – Universitätsmedizin Berlin and the Cleveland Clinic. Makharadze also supervised pharmacovigilance projects aligned with standards from the Council of Europe and engaged in training programs for clinicians modeled after curricula from the European Board for Accreditation in Cardiology.

Honors and awards

Throughout his career he received recognitions from professional societies and state institutions, including awards from the Georgian Academy of Sciences, the Ministry of Health (Georgia), and honors associated with regional medical congresses convened by the European Society of Cardiology and the World Congress of Cardiology. He was an invited speaker at conferences organized by the International Society of Hypertension, the International Society for Heart Research, and national meetings in Russia, Germany, France, and United Kingdom. His publications were cited by authors at institutions such as the University of Oxford, Harvard University, University of Toronto, and Uppsala University.

Personal life and legacy

Makharadze maintained professional ties with Georgian academic institutions including the Tbilisi State Medical Institute and the Ilia State University, mentoring physicians who later joined hospitals such as the Republican Clinical Hospital (Tbilisi) and research centers in Batumi and Kutaisi. His legacy appears in clinical protocols adopted in Georgian cardiology clinics and in collaborative networks linking Caucasus research groups with European centers including Munich University Hospital and the Institut Pasteur. He is remembered in obituaries and commemorative sessions held at national symposia sponsored by organizations like the Georgian Cardiology Society and international partners such as the European Society of Cardiology.

Category:Georgian physicians Category:Cardiologists Category:Clinical pharmacologists